Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 101–200 of 1,733
Cystic fibrosis bone disease treatment: Current knowledge and future directions
Putman, M. S., Anabtawi, A., Le, T. N. H., Tangpricha, V., & Sermet‐Gaudelus, I. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.017 · Cited by 78
Bhasin, S., Travison, T. G., Pencina, K. M., O’Leary, M. P., Cunningham, G. R., Lincoff, A. M., Nissen, S. E., Lucia, M. S., Preston, M. A., Khera, M., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.48692 · Cited by 92
Self-citationCozzi, R. C., Ambrosio, M. R., Attanasio, R., Battista, C., Bozzao, A., Caputo, M., CICCARELLI, E., Marinis, L. D., Menis, E. D., Fustini, M. F., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0977 · Cited by 77
Steroid secretion in healthy aging
Fiacco, S., Walther, A., & Ehlert, U. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.09.035 · Cited by 78
Diem, S. J., Greer, N. L., MacDonald, R. H., McKenzie, L. G., Dahm, P., Ercan-Fang, N. G., Estrada, A., Hemmy, L. S., Rosebush, C. E., Fink, H. A., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-0830 · Cited by 80
“Guidelines by the Endocrine Society (7) and American Urological Association (8) recommend that clinicians measure fasting morning concentrations of total testosterone on 2 occasions to diagnose hypogonadism but vary in their recommendations regarding the threshold at which to categorize a total testosterone level as l…”
BackgroundGender affirming medical care of transgender youth
Salas-Humara, C., Sequeira, G. M., Rossi, W. C., & Dhar, C. P. (2019) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2019.100683 · Cited by 96
Rastrelli, G., O'Neill, T. W., Ahern, T., Bártfai, G., Casanueva, F. F., Forti, G., Keevil, B., Giwercman, A., Han, T. S., Slowikowska‐Hilczer, J., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13756 · Cited by 69
Self-citationLotti, F., Frizza, F., Balercia, G., Barbonetti, A., Behre, H. M., Calogero, A. E., Cremers, J., Francavilla, F., Isidori, A. M., Kliesch, S., et al. (2020) · Andrology · doi:10.1111/andr.12808 · Cited by 76
“Only a few subjects showed FSH > 8 U/L, 36 hypogon-adotropic hypogonadism, 38,45,46 mild hyperprolactinemia, 39 or subclinical hypothyroidism.”
InfluentialBonnecaze, A. K., O’Connor, T., & Burns, C. A. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06751-3 · Cited by 91
“Reported doses commonly range between 500 and 1000 mg of testosterone per week,(7) which is 5–10 times the accepted treatment dose for male hypogonadism.(28) It is common for men using AAS to utilize injectable AAS for 8–16 weeks at a time, often referred to as a “cycle”.”
BackgroundMethodEffects of lifelong testosterone exposure on health and disease using Mendelian randomization
Mohammadi‐Shemirani, P., Chong, M., Pigeyre, M., Morton, R. W., Gerstein, H. C., & Paré, G. (2020) · eLife · doi:10.7554/elife.58914 · Cited by 73
Yeap, B. B., Marriott, R. J., Antonio, L., Chan, Y. X., Raj, S., Dwivedi, G., Reid, C. M., Anawalt, B. D., Bhasin, S., Dobs, A. S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa743 · Cited by 67
Self-citationUdeh-Momoh, C., & Watermeyer, T. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101459 · Cited by 67
Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors
van Iersel, L., Mulder, R. L., Denzer, C., Cohen, L. E., Spoudeas, H. A., Meacham, L. R., Sugden, E., Schouten-van Meeteren, A. Y. N., Hoving, E. W., Packer, R. J., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab040 · Cited by 66
Benefits and Risks of Testosterone Treatment in Men with Age-Related Decline in Testosterone
dos Santos, M. R., & Bhasin, S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-050219-034711 · Cited by 80
Self-citationTatem, A. J., Beilan, J., Kovac, J. R., & Lipshultz, L. I. (2020) · The World Journal of Men's Health · doi:10.5534/wjmh.190002 · Cited by 66
“Both the American Urological Association and the Endocrine Society published guidelines in 2018 which recommend against TTh in men wishing to preserve fertility [2,72].”
BackgroundPencina, K. M., Travison, T. G., Artz, A. S., Lincoff, A. M., Nissen, S. E., Flevaris, P., Chan, A., Li, X., Diegel, S. A., Wannemuehler, K. A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.40030 · Cited by 82
Self-citationHauger, R. L., Saelzler, U. G., Pagadala, M. S., & Panizzon, M. S. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09767-0 · Cited by 84
“0% being free testosterone unbound to sex hormone binding globulin (SHBG) or albumin [1, 2].”
BackgroundYeap, B. B., Marriott, R. J., Antonio, L., Raj, S., Dwivedi, G., Reid, C. M., Anawalt, B. D., Bhasin, S., Dobs, A. S., Handelsman, D. J., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0551 · Cited by 72
“We adjusted for 24 covariates, including age, not only BMI but also waist circumference, and factors that raise SHBG, such as thyroid and liver disease and anticonvulsantmedications (34).”
MethodSelf-citationCritical evaluation of different available guidelines for late‐onset hypogonadism
Giagulli, V. A., Castellana, M., Lisco, G., & Triggiani, V. (2020) · Andrology · doi:10.1111/andr.12850 · Cited by 73
Pizzocaro, A., Vena, W., Condorelli, R. A., Radicioni, A. F., Rastrelli, G., Pasquali, D., Selice, R., Ferlin, A., Foresta, C., Jannini, E. A., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01299-1 · Cited by 76
“This position has been endorsed by the US Endocrine Society [62] and by the Endocrine Society of Australia [63].”
Bone quality in endocrine diseases: determinants and clinical relevance
Cianferotti, L., Cipriani, C., Corbetta, S., Corona, G., Defeudis, G., Lania, A. G., Messina, C., Napoli, N., & Mazziotti, G. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02056-w · Cited by 68
Federici, S., Goggi, G., Quinton, R., Giovanelli, L., Persani, L., Cangiano, B., & Bonomi, M. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab043 · Cited by 73
Testosterone supplementation and bone parameters: a systematic review and meta-analysis study
Corona, G., Vena, W., Pizzocaro, A., Giagulli, V. A., Francomano, D., Rastrelli, G., Mazziotti, G., Aversa, A., Isidori, A. M., Pivonello, R., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01702-5 · Cited by 77
“According to available guidelines, testosterone replacement therapy (TRT) in the setting of male osteoporosis is particularly recommended in young adult hypogonadal men to prevent bone loss and help acquire peak bone mass [2, 9], and it should be associated with antiresorptive drugs when fracture risk is high [9, 11].”
BackgroundMcCullough, D., Webb, R., Enright, K. J., Lane, K. E., McVeigh, J., Stewart, C. E., & Davies, I. G. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09616-y · Cited by 62
“Nonetheless, TRT is only recommended for individuals who exhibit symptoms of testosterone deficiency (reduced libido, gynecomastia, depression, low bone mineral density, decreased energy, low muscle mass/strength and poor cardiovascular health profile) and low testosterone serum levels (< 12 nmol/l) [78, 79].”
BackgroundAlexandraki, K., & Grossman, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122153 · Cited by 62
“Its disadvantage is that it has to be injected in a large volume of 4 mL IM, and coughing episodes have been reported after injection in a small proportion of patients [10].”
BackgroundInfluentialIglesias, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134490 · Cited by 94
“Clinically, hypogonadal men present lower total and appendicular muscle mass, a higher proportion of body fat and a higher risk of falls and functional deterioration, especially with aging [47,50].”
Babcock, M. C., DuBose, L. E., Witten, T. L., Stauffer, B. L., Hildreth, K. L., Schwartz, R. S., Kohrt, W. M., & Moreau, K. L. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab715 · Cited by 73
Advancements in the gold standard: Measuring steroid sex hormones by mass spectrometry
Conklin, S. E., & Knezevic, C. E. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.03.008 · Cited by 71
Gava, G., Mancini, I., Cerpolini, S., Baldassarre, M., Seracchioli, R., & Meriggiola, M. C. (2018) · Clinical Endocrinology · doi:10.1111/cen.13821 · Cited by 65
Qaseem, A., Horwitch, C., Vijan, S. S., Etxeandia‐Ikobaltzeta, I., Kansagara, D. L., Forciea, M. A., Crandall, C., Fitterman, N., Hicks, L. A., Lin, J. S., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-0882 · Cited by 71
Pal, R., Aggarwal, A., Singh, T., Sharma, S., Khandelwal, N. K., Garg, A., Bhansali, A. K., Kumar, A., Yadav, U., Singh, P., et al. (2020) · European Geriatric Medicine · doi:10.1007/s41999-020-00332-z · Cited by 69
“5 gm/dl), diabetes mellitus (as per ADA definition) [16], hyperthyroidism (subclinical or overt), overt hypothyroidism, hypercalcemia, 25-hydroxyvitamin D < 10 ng/ ml, low serum testosterone in males (defined as testosterone levels below the lower limit of age-specific reference range) [17, 18], and elevated IgA tTg a…”
BackgroundChiang, J. M., Kaysen, G. A., Segal, M. R., Chertow, G. M., Delgado, C., & Johansen, K. L. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy252 · Cited by 69
An Assessment on Impact of COVID-19 Infection in a Gender Specific Manner
Agrawal, H., Das, N., Nathani, S., Saha, S., Saini, S. K., Kakar, S. S., & Roy, P. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10048-z · Cited by 65
Gorgey, A. S., Khalil, R. E., Gill, R. S., Gater, D. R., Lavis, T. D., Cardozo, C. P., & Adler, R. A. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2018.6136 · Cited by 64
Khripun, I., Vorobyev, S., Белоусов, И. И., Коган, М. И., & Zitzmann, M. (2018) · The Aging Male · doi:10.1080/13685538.2018.1506918 · Cited by 65
“The phenomenon is referred to as functional hypogonadism, as this particular type of testosterone deficiency exists without pathological correlate in the testes or hypothalamic/pituitary region (these conditions are known as classical hypogonadism) [7].”
BackgroundMale hypogonadism: pathogenesis, diagnosis, and management
de Silva, N. L., Papanikolaou, N., Grossmann, M., Antonio, L., Quinton, R., Anawalt, B. D., & Jayasena, C. N. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00199-2 · Cited by 78
Bhasin, S., Lincoff, A. M., Nissen, S. E., Wannemuehler, K. A., McDonnell, M. E., Peters, A. L., Khan, N., Snabes, M. C., Li, X., Li, G., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.7862 · Cited by 65
Self-citationPasiakos, S. M., Berryman, C. E., Karl, J. P., Lieberman, H. R., Orr, J. S., Margolis, L. M., Caldwell, J. A., Young, A. J., Montano, M. A., Evans, W. J., et al. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.07.059 · Cited by 54
“The increases in total and free testosterone above basal concentrations and the upper-end of the normal reference range were likely due to the administration of a greater dosage than the recommended initial dose for testosterone replacement therapy [28] and,possibly, thediscrepancybetweenactual endogenous testosterone…”
BackgroundInfluentialSex Hormones and Lung Inflammation
Reyes-García, J., Montaño, L. M., Carbajal-García, A., & Wang, Y.-X. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-68748-9_15 · Cited by 65
Anabolic androgenic steroids and cardiomyopathy: an update
Fadah, K., Gopi, G., Lingireddy, A., Blumer, V. L., DeWald, T. A., & Mentz, R. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1214374 · Cited by 77
Gencer, B., Bonomi, M., Adorni, M. P., Sirtori, C. R., Mach, F., & Ruscica, M. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09628-2 · Cited by 83
Aging and androgens: Physiology and clinical implications
Anawalt, B. D., & Matsumoto, A. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09765-2 · Cited by 55
Self-citationEndocrine complications of anorexia nervosa
Haines, M. S. (2023) · Journal of Eating Disorders · doi:10.1186/s40337-023-00744-9 · Cited by 77
“Among men, the diagnosis of functional hypogonadotropic hypogonadism relies on ascertaining symptoms and signs consistent with testosterone deficiency, obtaining at least two morning fasting testosterone levels with low or inappropriately normal gonadotropins, and excluding other causes of hypogonadotropic hypogonadis…”
BackgroundLiu, P. Y. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00683 · Cited by 55
“Until such data are available, expert societal guidelines will continue to caution against testosterone use in men with untreated severe OSA (74), despite a paucity of high-quality data examining the effect of testosterone therapy exclusively in men with OSA, and specifically in men with clinically significant OSA.”
BackgroundMethodLi, S., Zhao, Y., Yang, Y., Wang, X., Nie, M., Wu, X., Mao, J., & Veglio, F. (2020) · International Journal of Endocrinology · doi:10.1155/2020/4732021 · Cited by 65
Chemaitilly, W., Liu, Q., van Iersel, L., Ness, K. K., Li, Z., Wilson, C. L., Brinkman, T. M., Klosky, J. L., Barnes, N., Clark, K. L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00738 · Cited by 60
“The cutoff for testosterone, suggested by the assay manufacturer, was between the 5th to 10th percentiles in controls, in line with the accepted definition for hypogonadism.26 The LH value corresponding to the 97th percentile in controls was used as a cutoff in the absence of a standard definition for LCD.26 Testoster…”
BackgroundMethodResultInfluentialHow Does Physical Activity Modulate Hormone Responses?
Mennitti, C., Farina, G., Imperatore, A., Fonzo, G. D., Gentile, A., Civita, E. L., Carbone, G., Simone, R. R. D., Iorio, M. R. D., Tinto, N., et al. (2024) · Biomolecules · doi:10.3390/biom14111418 · Cited by 91
“Moreover, the presence of low testosterone levels alone, even in the absence of overt symptoms, may indicate “androgen deficiency,” underscoring the importance of comprehensive assessment and management in athletes [221,225,226].”
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management
Gangat, N., Szuber, N., & Tefferi, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26920 · Cited by 69
“ted, testosterone withheld until Hct is at an acceptable level <50%, and therapy resumed at a reduced dose.(141,142) In a large cohort of trans men (n = 1073), receiving testosterone and followed for”
BackgroundAnabolic-Androgenic Steroid Use in Sports, Health, and Society
BHASIN, S., HATFIELD, D. L., HOFFMAN, J. R., KRAEMER, W. J., LABOTZ, M., PHILLIPS, S. M., & RATAMESS, N. A. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002670 · Cited by 54
“The Endocrine Society Clinical Practice Guideline (148) details decision making regarding androgen therapy and the reader is referred to their specific guidelines on the diagnosis, treatment, and monitoring of hypogonadism in men (134).”
BackgroundMethodInfluentialSelf-citationTestosterone Deficiency: A Review and Comparison of Current Guidelines
Kwong, J. C. C., Krakowsky, Y., & Grober, E. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.03.262 · Cited by 55
Aulinas, A., Plessow, F., Asanza, E., Silva, L., Marengi, D. A., Fan, W., Abedi, P., Verbalis, J., Tritos, N. A., Nachtigall, L., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02608 · Cited by 54
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 137
Transdermal Drug Delivery Systems (TDDS): Recent Advances and Failure Modes
Ghaferi, M., Alavi, S. E., Phan, K. K. T., Maibach, H. I., & Mohammed, Y. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00211 · Cited by 72
Boden, W. E., Miller, M. G., McBride, R., Harvey, C., Snabes, M. C., Schmidt, J. M., McGovern, M. E., Fleg, J. L., Desvigne-Nickens, P. M., Anderson, T. J., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.03.016 · Cited by 58
Testosterone, Hypogonadism, and Heart Failure
Lodovico, E. D., Facondo, P., Delbarba, A., Pezzaioli, L. C., Maffezzoni, F., Cappelli, C., & Ferlin, A. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008755 · Cited by 62
Providing Care for Transgender Persons With Kidney Disease: A Narrative Review
Collister, D., Saad, N., Christie, E. A., & Ahmed, S. B. (2021) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358120985379 · Cited by 55
Low Testosterone in Adolescents & Young Adults
Cohen, J. A., Nassau, D. E., Patel, P., & Ramasamy, R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00916 · Cited by 68
“This threshold along with various others defining low total T set from 250 to 300 ng/dl by other societies such as the American Urological Association have been established regardless of age following many large-scale population studies (35).”
BackgroundPorcelli, T., Maffezzoni, F., Pezzaioli, L. C., Delbarba, A., Cappelli, C., & Ferlin, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0034 · Cited by 59
Giagulli, V. A., Castellana, M., Carbone, M. D., Pelusi, C., Ramunni, M. I., Pergola, G. D., Guastamacchia, E., & Triggiani, V. (2020) · Andrology · doi:10.1111/andr.12754 · Cited by 54
Anemia and Its Connections to Inflammation in Older Adults: A Review
Wacka, E., Nicikowski, J., Jarmużek, P., & Zembroń-Łacny, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072049 · Cited by 84
“These are the elements that favorably affect the hemoglobin and hematocrit levels in older men [133,134].”
BackgroundMechanisms of Central Hypogonadism
Barber, T., Kyrou, I., Kaltsas, G., Grossman, A., Randeva, H., & Weickert, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158217 · Cited by 50
Bhasin, S., Seidman, S. N., Travison, T. G., Pencina, K. M., Lincoff, A. M., Nissen, S. E., Miller, M. G., Flevaris, P., Li, X., Wannemuehler, K. A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae026 · Cited by 58
Self-citationAn overview on androgen-mediated actions in skeletal muscle and adipose tissue
Rizk, J. G., Sahu, R., & Duteil, D. (2023) · Steroids · doi:10.1016/j.steroids.2023.109306 · Cited by 65
“Male hypogonadism is a clinical syndrome consisting of symptoms and signs of androgen deficiency in combination with low serum testosterone [146].”
Testosterone, cognitive decline and dementia in ageing men
Yeap, B. B., & Flicker, L. A. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09728-7 · Cited by 62
Testosterone Therapy in Adolescent Boys: The Need for a Structured Approach
Stancampiano, M. R., Lucas-Herald, A. K., Russo, G., Rogol, A. D., & Ahmed, S. F. (2019) · Hormone Research in Paediatrics · doi:10.1159/000504670 · Cited by 56
Progress in nanoparticle-based electrochemical biosensors for hormone detection
Rossi, F., Trakoolwilaiwan, T., Gigli, V., Tortolini, C., Lenzi, A., Isidori, A. M., Thanh, N. T. K., & Antiochia, R. (2024) · Nanoscale · doi:10.1039/d4nr02075h · Cited by 52
Lenfant, L., Léon, P., Cancel‐Tassin, G., Audouin, M., Staerman, F., Rouprêt, M., & Cussenot, O. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.04.008 · Cited by 53
Haematological actions of androgens
Warren, A. M., & Grossmann, M. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101653 · Cited by 70
COVID-19 and the Endocrine System: A Review of the Current Information and Misinformation
Mirza, S. A., Sheikh, A. A. E., Barbera, M., Ijaz, Z., Javaid, M. A., Shekhar, R., Pal, S., & Sheikh, A. B. (2022) · Infectious Disease Reports · doi:10.3390/idr14020023 · Cited by 57
“However, the underlying mechanism of this finding remains a matter of debate, postulated mechanisms including infection-induced oxidative stress, hypothalamic–pituitary axis dysfunction due to acute severe infection and direct gonadal damage [44,45].”
BackgroundErectile Dysfunction and Oxidative Stress: A Narrative Review
Zhu, D., Pham, Q. M., Wang, C., Colonnello, E., Yannas, D., Hoai, B. N., Zhang, Y., Jannini, E. A., & Sansone, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073073 · Cited by 63
“Male hypogonadism is a clinical and biochemical syndrome featuring impaired testicular function, as expressed by reduced ability to produce testosterone and/or sperm cells [156–160].”
The Role of testosterone treatment in patients with metabolic disorders
Corona, G., Rastrelli, G., Vignozzi, L., Barbonetti, A., Sforza, A., Mannucci, E., & Maggi, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1938548 · Cited by 49
Loo, S. Y., Azoulay, L., Nie, R., Dell’Aniello, S., Yu, O. H. Y., & Renoux, C. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.03.022 · Cited by 54
Wang, J., Fan, X., Yang, M., Song, M., Wang, K., Giovannucci, E. L., Ma, H., Jin, G., Hu, Z., Shen, H., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1253 · Cited by 48
Testosterone Deficiency as One of the Major Endocrine Disorders in Chronic Kidney Disease
Romejko, K., Rymarz, A., Sadownik, H., & Niemczyk, S. (2022) · Nutrients · doi:10.3390/nu14163438 · Cited by 56
The role of leptin and low testosterone in obesity
Khodamoradi, K., Khosravizadeh, Z., Seetharam, D., Mallepalli, S. K. R., Farber, N., & Arora, H. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-022-00534-y · Cited by 58
“Thus, T should not be used to treat men with hypogonadotrophic hypogonadism who desire to have a child over the next year [200, 201].”
BackgroundEvolution of Guidelines for Testosterone Replacement Therapy
Park, H. J., Ahn, S. T., & Moon, D. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030410 · Cited by 48
“At present, four different official guidelines have been released from the International Society for the Study of the Aging Male (ISSAM) [7], Endocrine Society [8], International Society for Sexual Medicine (ISSM) [9], and American Urological Association (AUA) [10] and will be updated as necessary (Table 1).”
BackgroundMethodBurinkul, S., Panyakhamlerd, K., Suwan, A., Tuntiviriyapun, P., & Wainipitapong, S. (2021) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2021.05.003 · Cited by 53
Gender-Affirming Hormone Therapy for Transgender Men
Moravek, M. B. (2018) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000398 · Cited by 55
Boeri, L., Capogrosso, P., Ventimiglia, E., Pederzoli, F., Frego, N., Cazzaniga, W., Chierigo, F., Alfano, M., Piemonti, L., Viganò, P., et al. (2019) · BJU International · doi:10.1111/bju.14558 · Cited by 45
Factors Associated With Circulating Sex Hormones in Men: Individual Participant Data Meta-analyses
Marriott, R. J., Murray, K., Adams, R., Antonio, L., Ballantyne, C. M., Bauer, D. C., Bhasin, S., Biggs, M. L., Cawthon, P. M., Couper, D. J., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m23-0342 · Cited by 54
“A reference range for healthy nonobese young men has been proposed (9.2-31.8 nmol/L based on 2.5 th -97.5 th percentiles in men aged 19-39 years, for assays standardised to a higher order reference method established by the Centers for Disease Control and Prevention) (12).”
InfluentialSelf-citationGenetic analyses implicate complex links between adult testosterone levels and health and disease
Leinonen, J. T., Mars, N., Lehtonen, L. E., Ahola‐Olli, A., Ruotsalainen, S., Lehtimäki, T. J., Kähönen, M. A. P., Raitakari, O. T., Mars, N., Ruotsalainen, S., et al. (2023) · Communications Medicine · doi:10.1038/s43856-022-00226-0 · Cited by 52
Late‐onset Hypogonadism: Bone health
Rochira, V. (2020) · Andrology · doi:10.1111/andr.12827 · Cited by 50
Albrethsen, J., Johannsen, T. H., Jørgensen, N., Frederiksen, H. W., Sennels, H. P., Jørgensen, H. L., Fahrenkrug, J., Petersen, J. H., Linneberg, A. R., Nordkap, L., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa145 · Cited by 50
Hypogonadism in Pediatric Health: Adult Medicine Concepts Fail
Grinspon, R. P., Freire, A. V., & Rey, R. A. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.08.002 · Cited by 46
Yeap, B. B., & Wu, F. C. W. (2019) · Clinical Endocrinology · doi:10.1111/cen.13888 · Cited by 43
Self-citationPereira, B. I., Mazzitelli, M., Milinkovic, A., Casley, C., Rubio, J., Channa, R., Girometti, N., Asboe, D., Pozniak, A., & Boffito, M. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0083 · Cited by 49
“29 Sexual hormone-binding globulin (SHBG) levels were tested in 35.9% of patients, showing increased levels in 37.5%.”
InfluentialHackett, G., Cole, N., Mulay, A., Strange, R. C., & Ramachandran, S. (2019) · BJU International · doi:10.1111/bju.14536 · Cited by 43
Esteves, S. C., Humaidan, P., Ubaldi, F. M., Alviggi, C., Antonio, L., Barratt, C. L. R., Behre, H. M., Jørgensen, N., Pacey, A. A., Simoni, M., et al. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.103647 · Cited by 52
Gray, P. B., Straftis, A. A., Bird, B. M., McHale, T. S., & Zilioli, S. (2019) · Hormones and Behavior · doi:10.1016/j.yhbeh.2019.04.017 · Cited by 49
Male reproductive health in cystic fibrosis
Yoon, J. C., Leey, J., Litvin, M., & Dobs, A. S. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.007 · Cited by 55
Epidemiology of Male Hypogonadism
Thirumalai, A., & Anawalt, B. D. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.016 · Cited by 51
Testosterone Replacement Therapy in Hypogonadal Men
Wang, C., & Swerdloff, R. S. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.005 · Cited by 54
Self-citationTestosterone therapy and cardiovascular diseases
Cittadini, A., Isidori, A. M., & Salzano, A. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab241 · Cited by 46
Al‐Sharefi, A., & Quinton, R. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.760 · Cited by 52
“(CMAJ) [26], 2018 The American Urological Association (AUA) [27], 2018 European Association of Urology (EAU) [28], 2018 Endocrine Society (ES) [1] and, in 2016, The Endocrine Society of Australia position statement on MH (AUS) [29,30].”
BackgroundLisco, G., Bartolomeo, N., Tullio, A. D., Pergola, G. D., Guastamacchia, E., Jirillo, E., Piazzolla, G., Triggiani, V., & Giagulli, V. A. (2023) · Andrology · doi:10.1111/andr.13519 · Cited by 47
MECHANISMS OF ENDOCRINOLOGY: Mechanisms of disease: the endocrinology of obstructive sleep apnoea
Lavrentaki, A., Ali, A., Cooper, B. G., & Tahrani, A. A. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0411 · Cited by 51
Tan, S., Sohrabi, H. R., Weinborn, M., Tegg, M., Bucks, R. S., Taddei, K., Carruthers, M. E., & Martins, R. N. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.05.008 · Cited by 48
Is there a role for glucagon‐like peptide‐1 receptor agonists in the treatment of male infertility?
Cannarella, R., Calogero, A. E., Condorelli, R. A., Greco, E. A., Aversa, A., & Vignera, S. L. (2021) · Andrology · doi:10.1111/andr.13015 · Cited by 61
Giagulli, V. A., Castellana, M., Murro, I., Pelusi, C., Guastamacchia, E., Triggiani, V., & Pergola, G. D. (2019) · Nutrients · doi:10.3390/nu11122975 · Cited by 45
“The pathogenesis of this disorder is multifactorial and generally related to chronic diseases, including obesity, T2DM, and the metabolic syndrome [15,16].”
BackgroundMoreno, Ó., Merino, E., Alfayate, R., Quesada, M. E. T., Andrés, M., León‐Ramírez, J., Boix, V., Gil, J., & Pico, A. M. (2021) · Clinical Endocrinology · doi:10.1111/cen.14537 · Cited by 44
“22 nmol/L), according to the normal range for healthy young males in our laboratory.(13,14) CFT was calculated by determiningTT, sex hormone binding globulin (SHBG) and albumin from the equation described by Vermeulen et al.”
BackgroundMethod
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.